SCHEMBL20738595

SCHEMBL20738595

CC(=O)N(C)C1(C)CCC1

nearest known ligand 0.39

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
TSHR P16473 2/20 0.34
NFKB1 P19838 1/20 0.34
CYP2C19 P33261 1/20 0.34
FFAR3 O14843 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20738603 0.95 OPRM1 (0.39) OPRM1OPRL1TSHRNFKB1CYP2C19
SCHEMBL24272639 0.92 OPRM1 (0.38) OPRM1OPRL1TSHRFFAR3
SCHEMBL14501954 0.92 OPRM1 (0.38) OPRM1OPRL1TSHRFFAR3
SCHEMBL22667583 0.83 FFAR3 (0.50) OPRM1OPRL1FFAR3
SCHEMBL22667610 0.81 FFAR3 (0.48) OPRM1OPRL1CYP2C19FFAR3
SCHEMBL22667559 0.81 ALDH1A1 (0.38) OPRM1OPRL1
SCHEMBL28592530 0.79 FFAR3 (0.38) OPRM1OPRL1TSHRNFKB1CYP2C19
SCHEMBL20224888 0.78 KDM4E (0.36) OPRM1OPRL1
SCHEMBL22628157 0.77
Hydrochloric Acid SCHEMBL17848495 0.77 KDM4E (0.35) OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 OPRM1 571/4885OPRL1 918/4885TSHR 1190/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 OPRM1 571/4885OPRL1 918/4885TSHR 1190/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 OPRM1 572/4885OPRL1 921/4885TSHR 1152/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 OPRM1 571/4885OPRL1 918/4885TSHR 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.